Table of contents

• Overview of the research
• Who the trials include
• What the trials are trying to measure
• Trial phases and study status
• Key studies in the data
• Helpful terms for patients

Overview of the research

The trial data show that Sodium Oxybate is being studied in several different clinical settings, including brain disease, sleep medicine, addiction-related care, psychiatry, and intensive care.^{[1][2][3][4][5][6][7][8]}

These are interventional studies, which means the research team gives a treatment or compares treatments and then measures the results.^{[1][2][3][4][5][6][7][8]}

Who the trials include

The studies focus on different patient groups, so the people who may take part are not the same in every trial.^{[1][2][3][4][5][6][7][8]}

• People with cerebral amyloid angiopathy, a condition where amyloid builds up in brain blood vessels, are included in the Clear-Brain study.^[1]

• Adults with narcolepsy are included in a Phase 3 switch study that looks at blood pressure after changing treatment.^[2]

• People with alcohol addiction and a high or very high drinking risk level are included in a Phase 3 study of alcohol reduction and abstinence.^[5]

• Psychiatric patients with catatonia are included in a randomized study comparing Sodium Oxybate with lorazepam.^[6]

• Patients with GHB use disorder are included in detoxification studies that test whether baclofen can reduce the need for pharmaceutical GHB.^[4][7]

• Adults in the intensive care unit who have been hospitalized for more than 48 hours are included in a pilot sleep study, with or without mechanical ventilation.^[8]

• One study also includes people with intoxication and tests whether potential biomarkers can be detected longer than GHB itself in blood.^[3]

What the trials are trying to measure

Each trial has a primary endpoint, which is the main result used to judge the study.^{[1][2][3][4][5][6][7][8]}

• In cerebral amyloid angiopathy, the main endpoint is the morning levels of Aβ 40 and 42 in CSF, measured before and after treatment by lumbar puncture, which is a needle test to collect spinal fluid.^[1]

• In narcolepsy, the main endpoint is the change in 24-hour average SBP, which means systolic blood pressure, from the start of the study to the end-of-treatment visit.^[2]

• In the intoxication study, the main endpoint is the time until the longest detectable biomarker in blood is no longer changed in the treatment group compared with placebo, which is an inactive comparison treatment.^[3]

• In the GHB use disorder detoxification study, the main endpoint is the pharmaceutical GHB dose at the end of the titration phase during inpatient detoxification, which shows how much treatment is still needed.^[4][7]

• In alcohol addiction, the main endpoint is the reduction in HDDs, or heavy drinking days, after 3 months of treatment.^[5]

• In catatonia, the main endpoint is the response rate after four days, measured by the change in BFCRS scores, with response defined as a 50% reduction in symptoms.^[6]

• In the ICU sleep study, the main endpoint is the duration of deep slow-wave sleep, also called N3 stage, measured in minutes on sleep recordings.^[8]

Trial phases and study status

The data include Phase 2 and Phase 3 studies, plus one low-intervention trial.^{[1][2][3][4][5][6][7][8]}

Several studies are marked Authorised, two are Completed, and one is Withdrawn.^{[1][2][3][4][5][6][7][8]}

• Phase 2 studies in the data include cerebral amyloid angiopathy, GHB use disorder, and ICU sleep research.^[1][4][7][8]

• Phase 3 studies include narcolepsy, alcohol addiction, and catatonia.^[2][5][6]

• The completed studies are the narcolepsy switch study and the intoxication biomarker study.^[2][3]

• The withdrawn study is one of the inpatient GHB detoxification studies.^[4]

Key studies in the data

The Clear-Brain trial is a Phase 2 study in cerebral amyloid angiopathy and looks at whether treatment can increase amyloid-beta clearance from brain blood vessels, using CSF Aβ 40 and 42 as the main outcome.^[1]

The narcolepsy study is a Phase 3 switch trial that tests whether moving from high-sodium oxybate to XYWAV changes 24-hour blood pressure.^[2]

The intoxication trial is a low-intervention study that asks whether certain biomarkers in blood stay detectable longer than GHB itself.^[3]

The inpatient detoxification studies in GHB use disorder test whether baclofen add-on treatment lowers the amount of pharmaceutical GHB needed during titration.^[4][7]

The alcohol addiction study is a Phase 3 trial focused on reducing heavy drinking days and helping maintain abstinence in people with high drinking risk.^[5]

The catatonia study is a randomized Phase 3 trial comparing Sodium Oxybate with lorazepam and measuring symptom response after four days using BFCRS scores.^[6]

The ICU pilot study is a Phase 2 double-blind randomized controlled trial, which means neither the participants nor the researchers know who gets the study treatment, and it measures deep sleep time in critically ill adults.^[8]

Helpful terms for patients

Randomized controlled trial means people are assigned by chance to different groups so the results are more reliable.^[6][8]

Double-blind means the patient and the study team do not know which treatment is being given during the study.^[8]

Placebo means an inactive treatment used for comparison in research.^[3]

Lumbar puncture is a procedure that collects CSF from the lower back for testing.^[1]

Titration phase means a period when treatment is adjusted to find the right dose or amount used in the study.^[4][7]

Abstinence means not using alcohol.^[5]

Critical care or ICU care means treatment in a hospital unit for very sick patients who need close monitoring.^[8]

Biomarker means a measurable sign in the body, such as a blood or fluid test result, that researchers use to follow a disease or treatment effect.^[3]